AR119322A1 - Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl - Google Patents

Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl

Info

Publication number
AR119322A1
AR119322A1 ARP200101858A ARP200101858A AR119322A1 AR 119322 A1 AR119322 A1 AR 119322A1 AR P200101858 A ARP200101858 A AR P200101858A AR P200101858 A ARP200101858 A AR P200101858A AR 119322 A1 AR119322 A1 AR 119322A1
Authority
AR
Argentina
Prior art keywords
halogen
group
alkyl
optionally substituted
substituents independently
Prior art date
Application number
ARP200101858A
Other languages
English (en)
Inventor
Hans Richter
Fionn Ohara
Bernd Kuhn
Carsten Kroll
Benoit Hornsperger
Uwe Grether
Joerg Benz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119322A1 publication Critical patent/AR119322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de pirido-pirazina como inhibidores de monoacilglicerol lipasa (MAGL), composiciones farmacéuticas que los comprenden y la utilización de los mismos para el tratamiento o profilaxis de neuroinflamación, enfermedades neurodegenerativas, dolor, cáncer y trastornos mentales. Reivindicación 1: Compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en el que: R¹ se selecciona del grupo que consiste en: (i) arilo C₆₋₁₄ sustituido opcionalmente con 1 a 2 sustituyentes seleccionados independientemente del grupo que consiste en alcoxi C₁₋₆, halógeno y un grupo de fórmula (2), (ii) heteroarilo de 5 a 6 elementos sustituido opcionalmente con 1 a 2 sustituyentes seleccionados independientemente del grupo que consiste en halógeno, hidroxi, alcoxi C₁₋₆, -B(OH)₂, heteroarilo de 5 a 6 elementos, alquilo C₁₋₆, y amino, y (iii) heterociclilo de 5 a 14 elementos sustituido opcionalmente con 1 a 3 sustituyentes seleccionados independientemente del grupo que consiste en halógeno, alquilo C₁₋₆ y oxo, R² se selecciona del grupo que consiste en: (i) alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de halógeno, (ii) cicloalquilo C₃₋₁₄, (iii) arilo C₆₋₁₄ sustituido opcionalmente con 1 a 2 sustituyentes seleccionados independientemente de halógeno, (iv) heteroarilo de 5 a 14 elementos sustituido opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y oxo, y (v) heteroariloxi de 5 a 14 elementos sustituido opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y oxo, y (vi) heterociclilo de 5 a 14 elementos sustituido opcionalmente con 1 a 3 sustituyentes seleccionados independientemente de halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y oxo, R³ se selecciona del grupo que consiste en hidrógeno, halógeno, alcoxi C₁₋₆, cicloalquiloxi C₃₋₁₄ e hidroxi, R⁴ se selecciona del grupo que consiste en hidrógeno, halógeno, alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, alcoxiC₁₋₆-carbonilo, alcoxi C₁₋₆-carbonil-NH-, hidroxi, amino, carboxi, alquil C₁₋₆-C(O)-NH-, alquenil C₂₋₆-C(O)-NH-, carboxi-NH-, oxo, cicloalquilo C₃₋₁₄ e hidroxi-cicloalquilo C₃₋₁₄, L se selecciona del grupo que consiste en un enlace covalente y -CH=CH-, A se selecciona del grupo que consiste en arilo C₆₋₁₄, heteroarilo de 5 a 14 elementos y heterociclilo de 5 a 14 elementos, y n es 1, 2, 3 ó 4.
ARP200101858A 2019-07-03 2020-07-01 Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl AR119322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19184218 2019-07-03

Publications (1)

Publication Number Publication Date
AR119322A1 true AR119322A1 (es) 2021-12-09

Family

ID=67180549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101858A AR119322A1 (es) 2019-07-03 2020-07-01 Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl

Country Status (18)

Country Link
US (1) US20220213093A1 (es)
EP (1) EP3994137A1 (es)
JP (1) JP2022540367A (es)
KR (1) KR20220027991A (es)
CN (1) CN114072405A (es)
AR (1) AR119322A1 (es)
AU (1) AU2020299965A1 (es)
BR (1) BR112021026820A2 (es)
CA (1) CA3143280A1 (es)
CL (1) CL2022000005A1 (es)
CO (1) CO2022000749A2 (es)
CR (1) CR20210630A (es)
IL (1) IL288936A (es)
MA (1) MA56443A (es)
MX (1) MX2022000083A (es)
PE (1) PE20220514A1 (es)
TW (1) TW202116768A (es)
WO (1) WO2021001330A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MA53219A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
MX2022002311A (es) 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
CN115989228A (zh) 2020-09-03 2023-04-18 豪夫迈·罗氏有限公司 杂环化合物
WO2022266162A1 (en) 2021-06-16 2022-12-22 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) * 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors

Also Published As

Publication number Publication date
IL288936A (en) 2022-02-01
WO2021001330A1 (en) 2021-01-07
MA56443A (fr) 2022-05-11
CR20210630A (es) 2022-02-11
BR112021026820A2 (pt) 2022-02-22
AU2020299965A1 (en) 2022-02-03
MX2022000083A (es) 2022-02-03
JP2022540367A (ja) 2022-09-15
CA3143280A1 (en) 2021-01-07
KR20220027991A (ko) 2022-03-08
EP3994137A1 (en) 2022-05-11
TW202116768A (zh) 2021-05-01
CO2022000749A2 (es) 2022-02-07
CL2022000005A1 (es) 2022-10-21
PE20220514A1 (es) 2022-04-07
US20220213093A1 (en) 2022-07-07
CN114072405A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
AR119322A1 (es) Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
NZ766835A (en) Pharmaceutical compounds
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
AR120109A1 (es) Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
UY36207A (es) Inhibidores de la syk
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
EA201290237A1 (ru) Киназные ингибиторы
AR112834A1 (es) Derivados de rapamicina
EA201690752A1 (ru) Ингибиторы g12c kras
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
AR075587A1 (es) Derivados de bifenilo para el tratamiento de hepatitis c
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR097079A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
ECSP12011695A (es) Derivados de (tio) morfolina como moduladores de s1p
AR118515A1 (es) Compuestos y su uso en el tratamiento del cáncer
AR119234A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
PE20121338A1 (es) Derivados de piridino-piridinonas y su preparacion
AR091490A1 (es) Antagonistas de iap